• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+

by chantal | Dec 9, 2025 | Inzitagene Plasmivec, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Abundant development opportunities in immuno-oncology

by chantal | Nov 17, 2025 | Immunobody, Inzitagene Plasmivec, Moditope, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE Study Presentation, SITC (Society for Immunotherapy of Cancer) Annual Meeting, November 2025, National Harbor, MD

by chantal | Nov 7, 2025 | Immunobody, Inzitagene Plasmivec, SCIB1, Vaccines

Full steam ahead with iSCIB1+

by alex | Sep 11, 2025 | Inzitagene Plasmivec, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE’ing out iSCIB1+ in advanced melanoma

by alex | Aug 4, 2025 | Inzitagene Plasmivec, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell reports Strong Phase 2 Data on iSCIB1+ in Advanced Melanoma

by chantal | Jul 24, 2025 | Immunobody, Investor Presentations, Inzitagene Plasmivec

« Older Entries
Next Entries »

Recent Posts

  • Form F-4/A (November 2026)
  • NASDAQ listing, iSCIB1+, and ModiFy updates
  • Scancell Provides Corporate and Clinical Update
  • Notice of Annual General Meeting November 2026
  • Result of General Meeting

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy